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ABSTRACT 
 
 This study investigated the analgesic effects of a THC pro-drug in a rodent model of recurrent migraine. 
Rats received 4 nitroglycerin-induced (NTG: 10mg/kg/2ml) migraine episodes every third day for 12 days; saline, 
cremaphor-vehicle, propranolol (10mg/kg/ml), or THC-VAL-HS (0.5, 1.0, and 2.0 mg/kg/ml) were given IP 30 
minutes before NTG. Behavioral endpoints of photosensitivity, activity, orbital tightening, and tactile allodynia 
were assessed 110 m after NTG. Migraine severity increased over the course of the four episodes, pointing 
toward chronification and an important step in model validation. However, neither propranolol nor THC-VAL-HS 
significantly attenuated any of the migraine-related endpoints. These data are in contrast with clinical reports 
that marijuana mitigates migraine severity. These findings suggest that higher doses of THC-VAL-HS and/or 
other cannabinoid constituents in marijuana may be responsible for such anecdotal anti-migraine activity of 
cannabis.  
 
 
INTRODUCTION & BACKGROUND 
 
      As migraine research has progressed, 
the translational relevance of available 
models has improved. The first generation 
of models sought to determine the effects 
of administered nitroglycerine (NTG) in 
rats on the outcome of some potentially 
relevant clinical endpoints (Tassorelli et al. 
2003). In preliminary studies, rats were 
administered NTG and tested for signs of 
hyperalgesia, largely through the tail flick 
apparatus. This experiment found 
significant increases in hyperalgesia at 2 
and 4 hours post-NTG injection. These 
results validated a clinically relevant 
induction of migrane and revealed the 
possible role of nitrovasodilators in pain 
modulation. Though this experimental 
format may have had its merits, it lacked 
translational relevance to the clinical 
picture. The clinical need focuses on 
episodic migraine, which is characterized 
by recurrent migraine episodes. 
Additionally, the endpoints measured in 
this current model of migraine are not 
diagnostic criteria for migraine in the 
clinical picture.  
       In the second generation of migraine 
modelling, translational relevance 
improved by relying on multiple NTG 
administrations and migraine inductions 
(Pradhan et al. 2013). In this experiment, 
mice were injected with NTG every other 
day for 9 days, resulting in 5 total NTG 
injections. This experiment found 
significant increases in hyperalgesia related 
to von Frey mechanical sensitivity 
(technically these endpoints measured 
allodynia), and that these effects not only 
persisted, but worsened with episodic 
migraine induction. The implementation of 
recurrent NTG administration helped to 
improve the translational relevance of this 
migraine model, in regards to frequency, 
though they still neglected more clinically 
relevant endpoints of episodic migraine by 
focusing solely on hyperalgesia. 
        The third generation of migraine 
models sought to include more relevant 
diagnostic endpoints in its assessment of 
episodic migraine (Sufka et al. 2016). This 
experiment subjected rats to 5 NTG 
injections over the course of 15 days and 
measured the effect on the novel 
endpoints of expressed facial pain (using 
the Rat Grimace scale) and photophobia 
and decreased movement (both quantified 
using a Light/Dark box). The results of this 
experiment showed a significant decrease 
in locomotor activity and an increase in 
light sensitivity over the course of the five 
test sessions. These changes helped to 
further refine the model and aid in 
producing a more clinically relevant 
representation of the chronic migraine 
episodes necessary for a clinical diagnosis 
of episodic migraine.  
      The final generation of modelling, and 
the one that is utilized in this experiment, 
sought to add an additional clinically 
relevant endpoint representative of tactile 
allodynia (Harris et al. 2017). This 
experiment followed the recurrent 
administration of NTG that previous 
models utilized, but added a new 
apparatus in an attempt to quantify the 
development of tactile allodynia 
associated with chronification of migraine. 
This new apparatus is a circular arena 
consisting of two half fields of sandpaper 
of differing grit and seeks to quantify 
movement data as well as preference for 
one half field or the other. Through the 
implementation of this new apparatus, a 
significant increase in tactile allodynia, as 
measured by a decrease in movement and 
a preference for spending time on the 
smoother sandpaper, was recorded during 
the course of this experiment. However, 
this increase only occurred during the 5th 
episode, which indicates that tactile 
allodynia may be a more accurate indicator 
of the chronification of migraine. 
       Additionally, anecdotal evidence 
points to the possible efficacy of cannabis 
in alleviating symptoms of migraine. As 
early as the year 700 B.C.E., Indian 
ayurvedic medicine touted the ability of 
cannabis to be utilized for migraine pain 
(Russo, 1998). These anecdotal reports 
continued and persist even to this day, 
attesting to the possible benefits of 
cannabis use for migraine treatment 
(Russo, 1998).  
      However, reports of the analgesic 
properties of cannabis extend beyond 
anecdotal evidence and have been 
experimentally tested as well. A 1972 
study sought to compare the analgesic 
properties of THC to those of morphine 
(Buxbaum, 1972). To accomplish this goal, 
rats were administered intraperitoneal 
injections of THC or morphine and then 
subjected to hot plate and tail flick tests. 
This experiment found that an 
intraperitoneal injection of THC had 
analgesic effects equipotent to morphine 
in rats.  
       Furthermore, the analgesic effects of 
THC have also been demonstrated in 
human trials (Noyes Jr et al. 1975). Patients 
suffering from continuous pain attributed 
to cancer were administered varying doses 
of THC, and had their pain relief compared 
to the effects of codeine. This experiment 
found that a 20 mg dose of THC was 
slightly more effective at relief and 
reduction of pain than a 120 mg dose of 
codeine. This experiment speaks to the 
analgesic properties of THC and provides 
some validity for anecdotal efficacy in 
humans. 
      Thus, using both the recurrent 
migraine protocol with its clinically relevant 
endpoints and the evidence of THC’s 
efficacy as an analgesic, this study utilized 
a THC pro-drug formulation in the 
recurrent migraine model in rats . 
 
MATERIAL & METHODS 
 
Rats received 4 NTG migraine episodes 
every third day over a 12 day period. 
Nitroglycerin (10 mg/kg/2mL) was 
administered IP 30 minutes after IP 
injections of either saline, cremaphor-
vehicle, 20 mg/kg/mL propranolol or THC 
(0.5, 1.0, or 2.0 kg/mg/mL). Orbital 
tightening was captured 30 minutes post 
nitroglycerin administration. Behavioral 
endpoints were assessed 110 minutes post 
nitroglycerin administration and included 
measures of photophobia and activity in 
the light/dark box and spontaneous tactile 
allodynia in an arena. Sample sizes were n 
=.5-10.
RESULTS 
 
 
 
FIGURE 1. Weight Data- In general, weight increased for all test groups across all test 
sessions. On the day following a migraine episode, weight decreased among all groups. A 
significance was found for Day but there was no significant effect for Treatment and no 
significant Day x Treatment interaction.  
 
 
 
 
FIGURE 2. Orbital Tightening- Orbital tightening measures were collected 30 minutes post 
nitroglycerin administration. No systematic pattern showing changes or worsening of orbital 
tightening nor any separation among treatment groups in a consistent manner was detected 
from these data. No significant effect was found for Day or Treatment and there was no 
significant Day x Treatment interaction. 
 
 
 
FIGURE 3. Movement data in L/D Box- Mean movement data was collected 110 minutes post-
NTG administration. Movement generally decreased for all treatment groups across all test 
sessions. There was found to be a significant effect for Day, but no significant effect for 
Treatment and no significant Day x Treatment interaction.  
 
 
 
FIGURE 4. Photosensitivity in L/D Box- Time spent in light was quantified 110 minutes post-
NTG administration. Time spent in light generally decreased for all treatment groups across 
all test sessions. There was found to be a significant effect for Day, but no significant effect for 
Treatment and no significant Day x Treatment interaction. 
 
 
 
FIGURE 5. Movement Data in Open Arena- Mean movement data was collected 110 minutes 
post-NTG administration. Movement generally decreased for all treatment groups across all 
test sessions. A significant effect was found for Day, but there was no significant effect for 
Treatment and no significant Day x Treatment interaction. 
 
 
 
FIGURE 6. Time Spent in Half Field- Time spent on the 40-grit half of the open tactile arena 
was quantified 110 min post-NTG administration. There was a significant effect for Day, but 
no significant effect for Treatment and no significant Day x Treatment interaction. 
 
DISCUSSION  
 
      This experiment suffers from some 
limitations and has some opportunities to 
improve. First, orbital tightening is 
presented as an early indicator of 
photosensitivity, yet this measure is not 
temporally connected to measures of 
photosensitivity in the light-dark box. This 
experiment would benefit from having 
these two endpoints more closely linked, 
perhaps by removing subjects from the 
light-dark box to assess orbital tightening 
scores.  
       Second, data about weight 
progression and its relation to migraine-
induced nausea over the course of the 
recurrent migraine protocol is tenuous. 
Thus, we can only infer that these changes 
in weight data are related to migraine-
induced nausea simply because it appears 
to mirror the clinical presentation of 
migraine. Evidence that body weight 
changes in this “staircase” design may be 
a surrogate measure for nausea could be 
obtained from an experiment that utilized 
a compound that was known to induce 
nausea in animals.  
      Third, the novel measure of 
spontaneous tactile allodynia in the open 
arena could benefit from validation 
through additional studies. It would be 
beneficial to determine if this arena 
apparatus generalizes to other models that 
present spontaneous allodynia, such as a 
cisplatin-induced neuropathy model 
(Authier et al. 2000). If spontaneous 
allodynia in other models can be measured 
by movement in the arena apparatus, the 
next step would be to determine whether 
spontaneous allodynia differs from evoked 
allodynia in pharmacological sensitivity.  
       Finally, the absence of a prophylactic 
agent in attenuating these migraine 
endpoints is a limitation in regards to drug 
screening. Model validity could be greatly 
improved with an increase in 
pharmacological sensitivity. Efficacious and 
non-efficacious migraine therapies should 
screen positive and negative in the model, 
respectively, while also avoiding false 
positives and false negatives. 
 
 
 
 
 
 
 
CONCLUSION 
 
The current model of episodic migraine 
appears to accurately model chronification, 
though some of its paradigms could use 
validation with other measures. Neither 
propranolol nor THC-Val-HS attenuated any of 
the migraine endpoints on any test  
 
 
session. These data are in contrast with 
clinical reports that marijuana mitigates 
migraine severity. These findings suggest 
that higher doses of THC-VAL-HS and/or 
other cannabinoid constituents in 
marijuana may be responsible for such 
anecdotal anti-migraine activity of 
cannabis.
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